![Aug 23, 2023 · ³ Other LGMD targets in development: SRP-9005 (LGMD2C/R5 γ-sarcoglycan), SRP-9006 (LGMD2L/R12 Anoctamin 5), and SRP-9010 (LGMD2A/R1) Download PDF of Our Pipeline For more information about our pipeline, please contact Sarepta's Patient Affairs team at [email protected] . . Atandt dedicated internet pricing reddit](/img/512x512/1332887553249.webp)
We would like to show you a description here but the site won’t allow us. Sarepta’s gene therapy engine is tailored to specific disease states and aims to select individual components that target specific tissues and cells with the goal of optimizing expression of the select protein in those tissues. Together, these three components form what is called a construct . Jul 6, 2022 · SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche. Data are being presented this week at the 17th International Congress on Neuromuscular Diseases ... Jan 11, 2022 · The double-blind, placebo-controlled Study 102 is evaluating the safety, efficacy and tolerability of a single dose of SRP-9001 in 41 patients with DMD. Part 2 of the study evaluated SRP-9001 in ... May 3, 2022 · Patients treated with SRP-9001 generally maintained muscle strength (Time to Rise and 4-Stair Climb) and showed improvement in ambulation ability (100m) from baseline to Year 3. Conclusions: The observed safety profile and the enduring response following gene transfer provides proof-of-concept for the continuation of clinical trials assessing ... We would like to show you a description here but the site won’t allow us. Nov 28, 2022 · The BLA was supported by data from three studies: SRP-9001-101, SRP-9001-102 and SRP-9001-103. Cumulatively, these studies totaled more than 80 patients treated with SRP-9001, demonstrating positive efficacy measures at various time points up to four years after treatment. Extensive pre-clinical evidence also formed part of the BLA. We would like to show you a description here but the site won’t allow us. Jan 7, 2021 · About SRP-9001-102 Study SRP-9001-102 (Study 102) is a double-blind, 1:1 randomized, placebo-controlled clinical trial of SRP-9001 in 41 participants with Duchenne muscular dystrophy between the ... A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 (Delandistrogene Moxeparvovec) for Duchenne Muscular Dystrophy (DMD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Apr 27, 2020 · A detailed picture of the SRP-9001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided ... Nov 30, 2022 · According to a recent announcement, the FDA accepted and granted priority review to Sarepta Therapeutics ’ biologics license application (BLA) for SRP-9001, an investigative gene therapy for treating Duchenne muscular dystrophy (DMD), with a PDUFA date set for May 29, 2023. 1. "We are delighted to announce that the FDA has accepted Sarepta ... Apr 3, 2023 · The company has also pointed to signs, based on comparisons to historical controls, that patients who received SRP-9001 might be faring better than they would without treatment. The FDA has already approved multiple Duchenne drugs, including three of Sarepta’s, based on the idea that boosting dystrophin will lead to better function and health. Jan 11, 2022 · Participants in the trial will be given a single infusion of the gene therapy or placebo and be monitored for 52 weeks (about a year). Then, participants originally given SRP-9001 will get an infusion of placebo, and vice versa, followed by another year of monitoring. The study’s main goal is to measure changes in NSAA scores. Oct 1, 2022 · Delandistrogene moxeparvovec (SRP-9001) is an investigational gene transfer therapy developed for targeted skeletal and cardiac muscle expression of micro-dystrophin (a shortened, functional dystrophin protein). Apr 22, 2021 · SRP-9001 is an adeno-associated virus (AAV) mediated gene therapy that delivers a micro-dystrophin-encoding gene to the muscles and is intended as a curative treatment. The specific vector deployed in the gene transfer, AAVrh74, has been shown to achieve the efficient delivery of micro-dystrophin to skeletal muscle with tolerable immunogenicity ... Jun 22, 2023 · SRP-9001 is a novel DMD gene-replacement therapy co-invented by Dr. Mendell and Louise Rodino-Klapac, PhD, formerly at Nationwide Children’s and currently the executive vice president, head of Research and Development, and chief scientific officer at Sarepta Therapeutics. May 18, 2021 · About SRP-9001-103 (ENDEAVOR) Study SRP-9001-103 (Study 103) is an open-label clinical trial of SRP-9001 that has enrolled 20 participants with Duchenne muscular dystrophy between the ages of 4-7. May 12, 2023 · The vote, 8 to 6, came after a day of testimony from speakers for Sarepta Therapeutics, the maker of the gene therapy called SRP-9001, FDA scientists and families whose children have Duchenne ... Oct 5, 2021 · SRP-9001 is one of the leading investigational gene therapies that is being developed for treating DMD and the EMBARK study is the first pivotal study to evaluate any gene therapy for the indication. Sep 22, 2022 · Sarepta has already dosed 80 patients in clinical trials for SRP-9001, ranging from 3 to 19 years of age, with varying levels of ambulation. Its phase 3 trial, known as EMBARK, is enrolling 120 patients in the US and overseas. Later this year, Sarepta hopes to launch its second phase 3 study, ENVISION, for boys older than 8 years of age—both ... Apr 27, 2020 · A detailed picture of the SRP-9001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided ... Apr 10, 2023 · SRP-9001 (delandistrogene moxeparvovec) is an investigational gene transfer therapy intended to deliver SRP-9001 to muscle tissue for the targeted production of functional components of dystrophin. Sarepta is responsible for global development and manufacturing for SRP-9001 and plans to commercialize SRP-9001 in the United States upon receiving ... Apr 22, 2021 · SRP-9001 is an adeno-associated virus (AAV) mediated gene therapy that delivers a micro-dystrophin-encoding gene to the muscles and is intended as a curative treatment. The specific vector deployed in the gene transfer, AAVrh74, has been shown to achieve the efficient delivery of micro-dystrophin to skeletal muscle with tolerable immunogenicity ... Oct 5, 2021 · SRP-9001 is one of the leading investigational gene therapies that is being developed for treating DMD and the EMBARK study is the first pivotal study to evaluate any gene therapy for the indication. Jul 24, 2020 · About SRP-9001 SRP-9001 is an investigational gene transfer therapy designed to deliver the micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. Jun 22, 2023 · SRP-9001 could become a new standard of care in DMD. Mgmt. has suggested the peak revenue opportunity could exceed $4bn. SRPT share price fell by half when SRP-9001 flunked a Phase 2 study in ... May 12, 2023 · SRP-9001 is supported by non-clinical evidence in addition to efficacy and safety data from studies 101, 102 and 103 as well as an integrated analysis across these three clinical studies comparing ... Jan 7, 2021 · Study SRP-9001-102 (Study 102) is a double-blind, 1:1 randomized, placebo-controlled clinical trial of SRP-9001 in 41 participants with Duchenne muscular dystrophy between the ages of 4-7. Study 102 uses clinical process SRP-9001 and has two primary endpoints: micro-dystrophin expression at 12 weeks and change in NSAA total score at 48 weeks ... Nov 30, 2022 · According to a recent announcement, the FDA accepted and granted priority review to Sarepta Therapeutics ’ biologics license application (BLA) for SRP-9001, an investigative gene therapy for treating Duchenne muscular dystrophy (DMD), with a PDUFA date set for May 29, 2023. 1. "We are delighted to announce that the FDA has accepted Sarepta ... Jun 27, 2023 · Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy Nov 28, 2022 Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the ... May 3, 2022 · Patients treated with SRP-9001 generally maintained muscle strength (Time to Rise and 4-Stair Climb) and showed improvement in ambulation ability (100m) from baseline to Year 3. Conclusions: The observed safety profile and the enduring response following gene transfer provides proof-of-concept for the continuation of clinical trials assessing ... Nov 29, 2022 · SRP-9001 is designed to deliver a copy of a gene encoding micro-dystrophin — a shortened but functional version of the dystrophin protein, whose lack causes DMD — to muscle cells using a lab-engineered, harmless virus as a vector. Oct 1, 2022 · Delandistrogene moxeparvovec (SRP-9001) is an investigational gene transfer therapy developed for targeted skeletal and cardiac muscle expression of micro-dystrophin (a shortened, functional dystrophin protein). Jun 22, 2023 · For SRP-9001, the surrogate endpoint is a gene called micro-dystrophin, which codes for a shortened form of the dystrophin protein, measured 12 weeks after treatment with SRP-9001. In the US, there are four drugs which already have accelerated access for DMD, three of which are Sarepta’s, and all of which are exon skipping treatments. Jan 10, 2022 · SRP-9001-treated participants from the placebo crossover group (n=20, aged 5-8 at time of dosing SRP-9001) scored a statistically significant 2.0 points higher on the mean North Star Ambulatory ... Nov 28, 2022 · SRP-9001 is an investigational gene transfer therapy intended to deliver a micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. The SRP-9001 development program is sponsored by Sarepta Therapeutics, in partnership with Roche, and has been partially funded by PPMD. Jun 22, 2023 · SRP-9001 is a novel DMD gene-replacement therapy co-invented by Dr. Mendell and Louise Rodino-Klapac, PhD, formerly at Nationwide Children’s and currently the executive vice president, head of Research and Development, and chief scientific officer at Sarepta Therapeutics. Mar 23, 2023 · A set of consensus considerations for the management of relevant adverse events (AEs) related to the use of the investigational gene therapy delandistrogene maxeparvovec (SRP-9001; Sarepta Therapeutics) in the treatment of Duchenne muscular dystrophy (DMD) has been established by the Delphi panel, which reviewed data from 3 clinical trials of the therapy. 1 We would like to show you a description here but the site won’t allow us. Aug 23, 2023 · ³ Other LGMD targets in development: SRP-9005 (LGMD2C/R5 γ-sarcoglycan), SRP-9006 (LGMD2L/R12 Anoctamin 5), and SRP-9010 (LGMD2A/R1) Download PDF of Our Pipeline For more information about our pipeline, please contact Sarepta's Patient Affairs team at [email protected] . Jul 24, 2020 · About SRP-9001 SRP-9001 is an investigational gene transfer therapy designed to deliver the micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. Jul 6, 2022 · SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche. Data are being presented this week at the 17th International Congress on Neuromuscular Diseases ... Jan 5, 2023 · Ms. Borland discusses SRP-9001’s mechanism of action in terms of its 3 essential components, its vector, promoter, and transgene. She begins by explaining that SRP-9001 uses AAVrh74 as a vector, which was selected for its tissue selectivity for skeletal and cardiac muscle, as well as its low potential for pre-existing antibodies. Aug 10, 2022 · BLA filing of SRP-9001 for the treatment of patients with DMD is expected in fall of 2022; If filing and review go well then FDA Accelerated approval possible mid-2023. Aug 2, 2022 · SRP-9001 (delandistrogene moxeparvovec) is designed to deliver a gene encoding micro-dystrophin, a shortened but functional version of this protein, to muscle cells. The therapy delivers its genetic cargo using a specially designed viral vector. Nov 28, 2022 · SRP-9001 has been granted Priority Review by the FDA, with a regulatory action date of May 29, 2023. The company noted that SRP-9001 would be the first gene therapy for Duchenne. Sarepta is ... Jan 7, 2021 · About SRP-9001-102 Study SRP-9001-102 (Study 102) is a double-blind, 1:1 randomized, placebo-controlled clinical trial of SRP-9001 in 41 participants with Duchenne muscular dystrophy between the ... Apr 27, 2020 · A detailed picture of the SRP-9001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided ... Jul 6, 2022 · SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche. Data are being presented this week at the 17th International Congress on Neuromuscular Diseases ... Nov 30, 2022 · According to a recent announcement, the FDA accepted and granted priority review to Sarepta Therapeutics ’ biologics license application (BLA) for SRP-9001, an investigative gene therapy for treating Duchenne muscular dystrophy (DMD), with a PDUFA date set for May 29, 2023. 1. "We are delighted to announce that the FDA has accepted Sarepta ... Jan 10, 2022 · SRP-9001-treated participants from the placebo crossover group (n=20, aged 5-8 at time of dosing SRP-9001) scored a statistically significant 2.0 points higher on the mean North Star Ambulatory ... Aug 10, 2022 · BLA filing of SRP-9001 for the treatment of patients with DMD is expected in fall of 2022; If filing and review go well then FDA Accelerated approval possible mid-2023. Apr 27, 2020 · A detailed picture of the SRP-9001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided ... Jun 22, 2023 · SRP-9001 is a novel DMD gene-replacement therapy co-invented by Dr. Mendell and Louise Rodino-Klapac, PhD, formerly at Nationwide Children’s and currently the executive vice president, head of Research and Development, and chief scientific officer at Sarepta Therapeutics. Oct 5, 2021 · SRP-9001 is one of the leading investigational gene therapies that is being developed for treating DMD and the EMBARK study is the first pivotal study to evaluate any gene therapy for the indication. Apr 27, 2020 · A detailed picture of the SRP-9001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided ... Sep 22, 2022 · Sarepta has already dosed 80 patients in clinical trials for SRP-9001, ranging from 3 to 19 years of age, with varying levels of ambulation. Its phase 3 trial, known as EMBARK, is enrolling 120 patients in the US and overseas. Later this year, Sarepta hopes to launch its second phase 3 study, ENVISION, for boys older than 8 years of age—both ... Jan 7, 2021 · SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene, to muscle tissue, needed for muscle membrane stability. Nov 29, 2022 · SRP-9001 is designed to deliver a copy of a gene encoding micro-dystrophin — a shortened but functional version of the dystrophin protein, whose lack causes DMD — to muscle cells using a lab-engineered, harmless virus as a vector. Mar 23, 2023 · A set of consensus considerations for the management of relevant adverse events (AEs) related to the use of the investigational gene therapy delandistrogene maxeparvovec (SRP-9001; Sarepta Therapeutics) in the treatment of Duchenne muscular dystrophy (DMD) has been established by the Delphi panel, which reviewed data from 3 clinical trials of the therapy. 1 May 12, 2023 · In documents released Wednesday, FDA reviewers concluded Sarepta’s clinical trials “do not provide unambiguous evidence” that the therapy, known as SRP-9001, is “likely beneficial for ... Jul 6, 2022 · In the 20-patient Cohort 1 of SRP-9001-103 (ENDEAVOR), SRP-9001-treated participants improved 4 points from their pre-therapy baselines, and 3.8 points (unadjusted means) and 3.2 points (least squared means) at 52 weeks on the North Star Ambulatory Assessment (NSAA) compared to a propensity-weighted external control group (p=<0.0001) Nov 28, 2022 · SRP-9001 has demonstrated safety and efficacy in over 80 treated patients so far, with follow-up of up to 4 years post-treatment. The most recent data were presented from the ENDEAVOR study (Study SRP-9001-103; NCT04626674) in July 2022 and demonstrated an improvement of 4 points on the North Star Ambulatory Assessment (NSAA) from pre-therapy baselines in 20 participants at 52 weeks, as well ... Aug 2, 2022 · Equally impressive SRP-9001 treated patients improved 3.8 points on unadjusted means and 3.2 requiring of 52 weeks on NSAA compared to the propensity Master external control group, with a p-value ... Nov 28, 2022 · SRP-9001 has been granted Priority Review by the FDA, with a regulatory action date of May 29, 2023. The company noted that SRP-9001 would be the first gene therapy for Duchenne. Sarepta is ... Jun 22, 2023 · The FDA has approved Sarepta Therapeutics’ investigational gene therapy SRP-9001, otherwise known as delandistrogene moxeparvovec, for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. May 18, 2021 · About SRP-9001-103 (ENDEAVOR) Study SRP-9001-103 (Study 103) is an open-label clinical trial of SRP-9001 that has enrolled 20 participants with Duchenne muscular dystrophy between the ages of 4-7. May 12, 2023 · SRP-9001, otherwise known as delandistrogene moxeparvovec, is designed to deliver a copy of a gene encoding microdystrophin to muscle cells using a lab-engineered, harmless virus as a vector. It is prepared as a suspension of concentration of 1.33 x 1013 vg/mL, and is supplied in a single-use, 10 mL vial for a single-dose, intravenous infusion. We would like to show you a description here but the site won’t allow us. May 12, 2023 · SRP-9001 is supported by non-clinical evidence in addition to efficacy and safety data from studies 101, 102 and 103 as well as an integrated analysis across these three clinical studies comparing ... May 3, 2022 · Patients treated with SRP-9001 generally maintained muscle strength (Time to Rise and 4-Stair Climb) and showed improvement in ambulation ability (100m) from baseline to Year 3. Conclusions: The observed safety profile and the enduring response following gene transfer provides proof-of-concept for the continuation of clinical trials assessing ... Jan 20, 2023 · If Sarepta receives regulatory approval for its SRP-9001 therapy, its combined DMD-related sales could jump to $3.2 billion in DMD-related sales in 2028, led by SRP-9001’s $2 billion contribution. 29 Sarepta expects total peak sales for SRP-9001 to reach $4 billion. 30. SRP-9001 Changing Treatment Landscape for DMD Jan 10, 2022 · SRP-9001-treated participants from the placebo crossover group (n=20, aged 5-8 at time of dosing SRP-9001) scored a statistically significant 2.0 points higher on the mean North Star Ambulatory ... We would like to show you a description here but the site won’t allow us.
Aug 23, 2023 · ³ Other LGMD targets in development: SRP-9005 (LGMD2C/R5 γ-sarcoglycan), SRP-9006 (LGMD2L/R12 Anoctamin 5), and SRP-9010 (LGMD2A/R1) Download PDF of Our Pipeline For more information about our pipeline, please contact Sarepta's Patient Affairs team at [email protected] . . Visionworks eye exam dollar19
Oct 4, 2022 · SRP-9001 is designed to deliver a gene encoding micro-dystrophin (a shortened but functional version of the dystrophin protein) to the body’s muscle cells using a viral vector. The therapy is being co-developed by Sarepta and Roche. “If approved, SRP-9001 will be the first gene therapy available for Duchenne patients,” Ingram said. Nov 28, 2022 · SRP-9001 has been granted Priority Review by the FDA, with a regulatory action date of May 29, 2023. “We are delighted to announce that the FDA has accepted Sarepta’s BLA for SRP-9001 for ... Oct 4, 2022 · SRP-9001 is designed to deliver a gene encoding micro-dystrophin (a shortened but functional version of the dystrophin protein) to the body’s muscle cells using a viral vector. The therapy is being co-developed by Sarepta and Roche. “If approved, SRP-9001 will be the first gene therapy available for Duchenne patients,” Ingram said. A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 (Delandistrogene Moxeparvovec) for Duchenne Muscular Dystrophy (DMD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Jul 7, 2022 · Twenty participants in SRP-9001-103 (ENDEAVOR, NCT04626674) treated with SRP-9001 showed an improvement of 4 points on the North Star Ambulatory Assessment (NSAA) from pre-therapy baselines at 52 weeks, as well as a 3.8-point (unadjusted means) and 3.2-point (least squared means) improvement compared to a propensity-weighted external control ... May 11, 2023 · SRP-9001 is designed to deliver to muscle cells a gene encoding micro-dystrophin, a shortened version of the dystrophin protein, which is a protein that is lacking in DMD patients. Sarepta’s application is specifically based on data suggesting the therapy can increase micro-dystrophin levels as designed. Jun 22, 2023 · For SRP-9001, the surrogate endpoint is a gene called micro-dystrophin, which codes for a shortened form of the dystrophin protein, measured 12 weeks after treatment with SRP-9001. In the US, there are four drugs which already have accelerated access for DMD, three of which are Sarepta’s, and all of which are exon skipping treatments. Nov 29, 2022 · SRP-9001 is designed to deliver a copy of a gene encoding micro-dystrophin — a shortened but functional version of the dystrophin protein, whose lack causes DMD — to muscle cells using a lab-engineered, harmless virus as a vector. Jul 22, 2022 · Currently, four notable gene therapy candidates are under development: PF-06939926 from Pfizer, SRP-9001 from Sarepta Therapeutics, SGT-1001 from Solid Biosciences, and GNT 0004 from Genethon. There are two Ph3 trials registered at ClinicalTrials.gov to evaluate PF-06939926 and SRP-9001. These trials have an enrollment size of 99–120, and the ... Mar 18, 2023 · In advance of the upcoming regulatory action deadline for Sarepta Therapuetics’ investigational gene therapy for the treatment of Duchenne muscular dystrophy (DMD), delandistrogene moxeparvovec (also known as SRP-9001), the FDA has determined it will hold an advisory committee (AdComm) meeting. 1 The current Prescription Drug User Fee Act action date for the treatment’s biologics license ... Nov 28, 2022 · SRP-9001 has been granted Priority Review by the FDA, with a regulatory action date of May 29, 2023. The company noted that SRP-9001 would be the first gene therapy for Duchenne. Sarepta is ... Mar 18, 2023 · In advance of the upcoming regulatory action deadline for Sarepta Therapuetics’ investigational gene therapy for the treatment of Duchenne muscular dystrophy (DMD), delandistrogene moxeparvovec (also known as SRP-9001), the FDA has determined it will hold an advisory committee (AdComm) meeting. 1 The current Prescription Drug User Fee Act action date for the treatment’s biologics license ... May 12, 2023 · SRP-9001, otherwise known as delandistrogene moxeparvovec, is designed to deliver a copy of a gene encoding microdystrophin to muscle cells using a lab-engineered, harmless virus as a vector. It is prepared as a suspension of concentration of 1.33 x 1013 vg/mL, and is supplied in a single-use, 10 mL vial for a single-dose, intravenous infusion. Nov 28, 2022 · SRP-9001 is an investigational gene transfer therapy intended to deliver a micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. The SRP-9001 development program is sponsored by Sarepta Therapeutics, in partnership with Roche, and has been partially funded by PPMD. A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 (Delandistrogene Moxeparvovec) for Duchenne Muscular Dystrophy (DMD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Nov 28, 2022 · SRP-9001 has demonstrated safety and efficacy in over 80 treated patients so far, with follow-up of up to 4 years post-treatment. The most recent data were presented from the ENDEAVOR study (Study SRP-9001-103; NCT04626674) in July 2022 and demonstrated an improvement of 4 points on the North Star Ambulatory Assessment (NSAA) from pre-therapy baselines in 20 participants at 52 weeks, as well ... Jun 27, 2023 · Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy Nov 28, 2022 Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the ... May 12, 2023 · SRP-9001 is supported by non-clinical evidence in addition to efficacy and safety data from studies 101, 102 and 103 as well as an integrated analysis across these three clinical studies comparing ... .